COMMUNIQUÉS West-GlobeNewswire

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism
02/06/2026
Growing momentum for RAS inhibition at ASCO highlights Namodenoson’s RAS pathway inhibition and encouraging data in pancreatic cancer Ramat Gan, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE [...]
The Ensign Group Purchases Memory Care Facility in California
02/06/2026
SAN JUAN CAPISTRANO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
02/06/2026
Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe [...]
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
02/06/2026
ACTON, Mass. and CARLSBAD, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) (NASDAQ: BJDX), a medical diagnostics company focused on near-patient testing for critical care [...]
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
02/06/2026
Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study’s primary endpoint Topline results for the fully enrolled open-label study are expected in the second half of 2026 [...]
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
02/06/2026
In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M. Moshfeghi, MD Company to highlight AXPAXLI™ wet [...]
CorVel Marks 35 Years on Nasdaq, Signals Next Phase of Long-Term Innovation and Growth
02/06/2026
FORT WORTH, Texas, June 02, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) today announced that it will mark its 35th anniversary as a publicly traded company listed on the Nasdaq Stock Market. Members of [...]
Soleo Health Acquires Realo Specialty Care Pharmacy and BluHaven Management, Expanding Footprint in Mid-Atlantic Region
02/06/2026
FRISCO, Texas and MORRISVILLE, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Soleo Health, an independent specialty pharmacy and infusion therapy provider, announced today the Company acquired Realo Specialty Care Pharmacy (“ [...]
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
02/06/2026
RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
02/06/2026
Two regenerative aesthetic and longevity products, with clinically validated ingredients , are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to [...]
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
02/06/2026
Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors Durable survival benefit: 12-month [...]
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
02/06/2026
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect. Efficacy was [...]
Philips announces exchange ratio for 2025 dividend
02/06/2026
June 2, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year 2025 is 1 new common share for every 26.9341 existing common shares. [...]
Bavarian Nordic Launches Next Tranche of Share Buy-Back Program
02/06/2026
COPENHAGEN, Denmark, June 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the third and final tranche of the planned buy-back program, under which the Company intends to repurchase own shares for up to DKK 500 [...]
OXB Capital Markets Event
02/06/2026
OXB to demonstrate how its global, multi-vector CDMO platform is positioned to capture growth in the cell and gene therapy market Event to highlight OXB’s proven track record, leading technical capabilities, expanded [...]
Nanobiotix rejoint l'indice Euronext Tech Leaders
02/06/2026
PARIS et CAMBRIDGE, Mass., 02 juin 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
02/06/2026
Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and execution as the [...]
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
02/06/2026
Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals Two oral presentations of novel, [...]
Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types
02/06/2026
Data from Phase 1b EMITT-1 trial presented in oral session at ASCO 2026 Annual Meeting First-in-class oral ERAP1 inhibitor demonstrates objective response rates (ORR) of 13–36% across patients with secondary anti-PD-1 [...]

Pages